Literature DB >> 15639720

Anticoagulant drugs increase natural killer cell activity in lung cancer.

V Bobek1, M Boubelik, A Fiserová, M L'uptovcová, L Vannucci, G Kacprzak, J Kolodzej, A M Majewski, R M Hoffman.   

Abstract

BACKGROUND: In preclinical studies in animal models and in initial clinical trials, anticoagulation drugs have been shown to be effective in the prevention and treatment of haematogenous metastasis, and in the prolongation of survival in animal models. However, only a few studies have been performed on the direct influence of anticoagulation drugs on the immune system.
OBJECTIVE: The purpose of this study is to determine the effect of warfarin, unfractioned heparin, low molecular weight heparins (LMWHs), and acetylsalicylic acid anticoagulants on the functional activity of natural killer (NK) cells. PATIENTS AND
METHOD: Cytotoxic activity in patients with early, operable stages of non-small-cell lung cancer was compared with healthy volunteers. Cytotoxic studies were also carried out in tumor-bearing animals.
RESULTS: Lung-cancer patients were characterized by significantly lower NK cell cytotoxicity (7.07 +/- 3.15) than healthy donors (44.12 +/- 10.62, P < 0.001). NK cell activation was found in both in vitro experiments using peripheral blood mononuclear cells (PBMC) from healthy donors and ex vivo in lung carcinoma patients after treatment with unfractionated heparin and fraxiparine. Similarly, potentiation of NK cell activity in Lewis lung carcinoma-bearing mice was found after therapy with unfractionated heparin. NK cell activity is lower in lung cancer patients than in normal subjects.
CONCLUSIONS: NK cell activation was increased by LMWHs. Other anticoagulants augment the effector function of NK cells in cancer patients and in an animal model of lung cancer. This is a novel effect of these compounds, which were thought previously to exert their effect only via their anticoagulant properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639720     DOI: 10.1016/j.lungcan.2004.06.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

Review 1.  Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.

Authors:  Ning Zhang; Weihua Lou; Fang Ji; Lihua Qiu; Benjamin K Tsang; Wen Di
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-24       Impact factor: 4.553

Review 2.  Thromboembolic disease in cancer patients.

Authors:  Nadia Hindi; Nazaret Cordero; Enrique Espinosa
Journal:  Support Care Cancer       Date:  2013-02-21       Impact factor: 3.603

Review 3.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

Review 4.  The impact of warfarin on overall survival in cancer patients.

Authors:  Thita Chiasakul; Jeffrey I Zwicker
Journal:  Thromb Res       Date:  2021-11-14       Impact factor: 10.407

5.  NK cell-mediated cytotoxicity modulation by A(2) adenosine receptor agonist in different mammalian species.

Authors:  M Kuldová; J Svoboda; F Kovárů; L Vannucci; H Kovárů; A Fiserová
Journal:  Folia Microbiol (Praha)       Date:  2009-10-14       Impact factor: 2.099

6.  Rectal bleeding and previous anticoagulant treatment in patients with colorectal cancer do not predict outcome.

Authors:  B Kirshtein; S Ariad; S Mizrahi; S Man; S Walfisch
Journal:  Tech Coloproctol       Date:  2007-05-25       Impact factor: 3.781

7.  Urbanization and anticoagulant poisons promote immune dysfunction in bobcats.

Authors:  Laurel E K Serieys; Amanda J Lea; Marta Epeldegui; Tiffany C Armenta; Joanne Moriarty; Sue VandeWoude; Scott Carver; Janet Foley; Robert K Wayne; Seth P D Riley; Christel H Uittenbogaart
Journal:  Proc Biol Sci       Date:  2018-01-31       Impact factor: 5.349

8.  The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.

Authors:  Jeroen T Buijs; El H Laghmani; Rob F P van den Akker; Chris Tieken; Esther M Vletter; Kim M van der Molen; Juliette J Crooijmans; Chantal Kroone; Sylvia E Le Dévédec; Gabri van der Pluijm; Henri H Versteeg
Journal:  J Thromb Haemost       Date:  2019-04-29       Impact factor: 5.824

Review 9.  Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.

Authors:  Steven K Yarmoska; Ali M Alawieh; Stephen Tomlinson; Kimberly B Hoang
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

10.  Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.

Authors:  S M Sagar; D Yance; R K Wong
Journal:  Curr Oncol       Date:  2006-02       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.